ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Chugai Pharmaceutical Co., Ltd.

  • 7,380.00 JPY
  • -80.00
  • -1.07%
  • Japan
    Aug 23, 2019
  • Ticker
  • Prev. close
  • Market cap (JPY)
  • Market cap (USD)
  • Shares

Business Summary

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety. The Research division focuses its efforts on creating innovative drugs by using its competitive strengths that include proprietary antibody technologies and cutting-edge research resources. The Development division provides cross-functional lifecycle management system to deliver innovative medicines to patients as quickly as possible. The Production division provides a world-class safety and quality management systems. The Marketing division conducts patient-oriented marketing activities to help solve issues related to healthcare. The Medical Affairs division works to properly deliver the value of medicines based on global compliance standards. The Drug Safety provides safety management system includes expert safety evaluation as well as timely gathering and reporting of safety information. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2018 JPYUSD
Gross Profit316,025M2,861.43M
Operating income129,225M1,170.06M
Income before tax121,449M1,099.65M
Net income92,488M837.42M
Diluted EPS168.791.52
Dividends Per Share860.77
Total Assets919,548M8,381.24M
Total liabilities163,020M1,485.84M
Total equity755,865M6,889.34M
Operating cash flow119,269M1,079.91M
Currency in JPYCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 461,109M 498,839M 491,780M 534,199M 579,787M
Gross Profit 244,079M 258,523M 243,553M 279,574M 316,025M
Operating income 77,734M 88,838M 79,320M 102,973M 129,225M
Income before tax 76,164M 87,276M 74,448M 97,031M 121,449M
Net income 50,980M 61,125M 53,592M 72,714M 92,488M
EBITDA 92,614M 104,405M 95,689M 119,307M 145,803M
Diluted EPS 93.38 111.79 97.97 132.83 168.79
Dividends Per Share 48 58 52 62 86
Total Assets 739,538M 787,401M 806,285M 852,473M 919,548M
Total liabilities 141,782M 160,130M 159,789M 159,576M 163,020M
Total equity 596,099M 625,857M 645,508M 691,924M 755,865M
Operating cash flow 37,518M 63,266M 39,080M 107,889M 119,269M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 4,356.24M 4,120.42M 4,525.90M 4,763.94M 5,249.65M
Gross Profit 2,305.89M 2,135.40M 2,241.44M 2,493.22M 2,861.43M
Operating income 734.37M 733.80M 729.99M 918.30M 1,170.06M
Income before tax 719.54M 720.90M 685.15M 865.31M 1,099.65M
Net income 481.62M 504.89M 493.21M 648.45M 837.42M
EBITDA 874.95M 862.38M 880.63M 1,063.97M 1,320.16M
Diluted EPS 0.88 0.92 0.90 1.18 1.52
Dividends Per Share 0.45 0.47 0.47 0.55 0.77
Total Assets 6,168.21M 6,545.58M 6,912.89M 7,567.44M 8,381.24M
Total liabilities 1,182.55M 1,331.14M 1,369.99M 1,416.56M 1,485.84M
Total equity 4,971.84M 5,202.68M 5,534.42M 6,142.24M 6,889.34M
Operating cash flow 354.44M 522.57M 359.65M 962.14M 1,079.91M

Valuation Measures

Dec 2018
Operating margin22.28%
Profit margin15.95%

Key executives

  • President, CEO & Representative Director: Tatsuro Kosaka
  • CFO, Manager-Information Technology & Accounting: Itagaki Toshiaki
  • Executive Officer & GM-Clinical Development: Hisanori Takanashi
  • Senior Executive Officer & Head-Research: Hisafumi Okabe
  • Executive Officer: Toshihiko Komori


  • Roche Holding AG (59.8%)
  • Nomura Asset Management Co., Ltd. (2.6%)
  • Wellington Management Co. LLP (2.4%)
  • Capital Research & Management Co. (World Investors) (2.3%)
  • Chugai Pharmaceutical Co., Ltd. (2.1%)
  • Nikko Asset Management Co., Ltd. (1.3%)
  • Daiwa Asset Management Co. Ltd. (1.2%)
  • The Vanguard Group, Inc. (1.0%)
  • BlackRock Fund Advisors (0.6%)
  • Norges Bank Investment Management (0.6%)

Contact Details

  • Website:
  • Address: Nihonbashi Mitsui Tower, 15/F, 2-1-1 Nihonbashi-Muromachi, Tokyo, 103-8324, Japan
  • Phone: +81.3.3281.6611

Related Companies

  • Chugai Pharmaceutical Co. Ltd. /Ulcerlmin Bus/
  • Chugai Distribution Co., Ltd.
  • Medical Culture YK
  • Chugai Business Support Co., Ltd.
  • Chugai Clinical Research Center Co., Ltd.
  • Chugai Pharma Technology Taizhou Co., Ltd.
  • Chugai Pharmaceutical Restricted Stock Compensation Plan
  • Chugai Pharma Consulting (Shanghai) Co., Ltd.
  • Chugai Pharma R&D Taiwan Ltd.
  • Chugai Pharma China Co., Ltd.
  • Chugai Pharma Science (Beijing) Co., Ltd.
  • Chugai Pharma Taiwan Ltd.
  • Chugai Pharmabody Research Pte Ltd.
  • Pharmalogicals Research Pte Ltd.
  • Forerunner Pharma Research Co., Ltd.
  • Chugai Research Institute for Medical Science, Inc.
  • Chugai Pharma Manufacturing Co., Ltd.
  • Chugai Pharmaceutical Employee Stock Ownership Plan
  • Chugai Pharma Development Ltd.
  • Chugai Pharma U.K. Ltd.
  • Chugai Pharma France SAS
  • Chugai USA, Inc.
  • Chugai Biopharmaceuticals, Inc.
  • Chugai Pharma USA LLC
  • Nippon Roche KK


  • Regeneron Pharmaceuticals, Inc.
  • Harpoon Therapeutics, Inc.
  • Cara Therapeutics Inc
  • BioLineRX Ltd.
  • Portola Pharmaceuticals, Inc.
  • Ascendis Pharma A/S Sponsored ADR
  • Dermira Inc
  • InflaRx N.V.
  • Kiniksa Pharmaceuticals Ltd. Class A
  • MagForce AG
Last Updated on 23 Aug, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media